Form 4: Beam Therapeutics SVP, Finance and Treasurer, Bethany J Cavanagh, Acquires 5,000 Stock Options

Bethany J Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics, reports the acquisition of 5,000 stock options.

Summary

• On August 31, 2024, Bethany J Cavanagh, the SVP, Finance and Treasurer of Beam Therapeutics Inc., acquired 5,000 stock options.
• The exercise price of these options is $26.68.
• The options vest in equal monthly installments over 48 months following the grant date, contingent upon continued service with Beam Therapeutics Inc.
• The expiration date for these options is August 31, 2034.
• Following this transaction, Cavanagh directly owns 5,000 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock option acquisition. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider transactions.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is required when an insider of a publicly traded company buys or sells the company's securities. It provides transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may view this as a positive sign if they believe the executive's confidence in the company is reflected in the stock option acquisition.

Key Dates